Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Distinctive pathological features of inherited and sporadic late-onset nemaline myopathies
Neuromuscular and Clinical Neurophysiology (EMG)
P10 - Poster Session 10 (5:30 PM-6:30 PM)
1-008

To identify histological features distinguishing inherited nemaline myopathies (iNM) from sporadic late-onset nemaline myopathy (SLONM). 

iNM are a genetically heterogeneous group of disorders characterised by accumulation of Z-disc derived nemaline rods in muscle fibres and manifesting in infancy to adulthood. Nemaline rods are also a pathological feature of SLONM, an acquired myopathy sometimes associated with monoclonal gammopathies or HIV infection. Identification of pathological parameters distinguishing these two myopathies has significant implications, as SLONM may respond to pharmacological therapy.

The clinical and histological characteristics of iNM and SLONM patients were reviewed. Muscle fibre sizes and the proportion of fibres harbouring nemaline rods were determined using unbiased sampling methods.

We randomly selected 9 patients with iNM and 10 with non-HIV SLONM. Their median ages were 11 and 64 years, respectively. The causative genes in iNM were ACTA1 (3 patients), NEB (1 patient) or unknown (5 patients, aged 2-11). Six SLONM patients had monoclonal gammopathies. The proportion of fibres harbouring nemaline rods was higher in iNM (median 53%, range: 39-99%) than in SLONM (median 11%, range: 1.2-47%). In SLONM, fibres containing nemaline rods had a smaller diameter than fibres devoid of rods (median ratio 0.60), while the opposite was observed in iNM (median ratio 1.12). Atrophic fibres filled with rods occurred in 8/10 SLONM patients and, less conspicuously, in 1/9 iNM patients. In 6/10 SLONM patients, nemaline rods were spread diffusely within the individual fibres, while rods occurred in clusters in 8/9 iNM patients. Necrotic fibres were present in 7/10 SLONM patients, but only in 1/9 iNM patients.

Pathological findings can distinguish SLONM from iNM. These findings, combined with the clinical history, are crucial for differentiating SLONM from adult-onset iNM, particularly when an underlying genetic defect is not detected. This distinction allows the identification of patients amenable to treatment. 

Authors/Disclosures
Stefan Nicolau, MD (Nationwide Children's Hospital)
PRESENTER
The institution of Dr. Nicolau has received research support from Muscular Dystrophy association. The institution of Dr. Nicolau has received research support from American Brain Foundation. The institution of Dr. Nicolau has received research support from American Neuromuscular Foundation.
No disclosure on file
Duygu Selcen, MD, FÂé¶¹´«Ã½Ó³»­ (Mayo Clinic) Dr. Selcen has nothing to disclose.
Andrew G. Engel, MD, FÂé¶¹´«Ã½Ó³»­ (Mayo Clinic Rochester) The institution of Dr. Engel has received research support from NIH.
No disclosure on file
Margherita Milone, MD, FÂé¶¹´«Ã½Ó³»­ (Mayo Clinic) Dr. Milone has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cartesian Therapeutics. Dr. Milone has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology Genetics, Âé¶¹´«Ã½Ó³»­. The institution of Dr. Milone has received research support from Mayo Clinic, CCaTS-CBD. The institution of Dr. Milone has received research support from Mayo Clinic, SGP Award. The institution of Dr. Milone has received research support from MDA for Care Center grant. The institution of Dr. Milone has received research support from Regenerative medicine Minnesota.